Gyroscope Therapeutics
A clinical-stage gene therapy company focused on treating diseases of the eye.
Gyroscope's lead investigational gene therapy, GT005, is being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
It has received Fast Track designation from the US Food and Drug Administration and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with GA.
Latest Gyroscope Therapeutics News & Features
12 September 2023
10 November 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze